Bayer AG ADR Stock
Bayer AG ADR Stock
Pros and Cons of Bayer AG ADR in the next few years
Pros
Cons
Performance of Bayer AG ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Bayer AG ADR | 4.480% | 6.061% | 0.719% | -52.055% | -18.605% | -47.368% | -52.055% |
| Roche Holding AG ADR | -0.530% | -4.221% | -5.489% | -20.318% | -13.589% | -17.416% | - |
| Novo Nordisk A/S ADR | 1.690% | 0.000% | 0.837% | -20.724% | 28.465% | 95.617% | 175.114% |
| Astrazeneca ADR | 1.420% | 7.519% | 13.492% | 7.519% | 16.260% | 61.765% | - |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.The financials of Bayer, a leading Pharmaceuticals company with the US symbol BAYRY, appear to exhibit a promising outlook, although some areas could use improvement. Boasting an increasing trend in total assets and revenue, the company seems to be on a path of growth. However, a closer examination will reveal both the advantages and limitations of Bayer's financial performance.
Rising Total Assets: Bayer's total assets have consistently increased over the past three years (2020-2022). This is a strong indicator of the company's sustainable growth and its ability to accumulate tangible and intangible resources over time.
Growing Total Revenue: The company's total revenue has also increased over the years, demonstrating its capacity to generate higher sales and achieve business profitability. This upward trend in revenue is a positive sign for investors and stakeholders.
Comments
